Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Most Appropriate Prescription of the First-line, the Second-line, and the Third Treatment for H. Pylori Eradication Among Patients Who Are Comorbid Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, or Chronic Kidney Disease

NCT05475431 is registered in ClinicalTrials.gov with National Cheng-Kung University Hospital as lead sponsor.

NCT NCT05475431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05475431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Most Appropriate Prescription of the First-line, the Second-line, and the Third Treatment for H. Pylori Eradication Among Patients Who Are Comorbid Diabetes Mellitus, Chronic Obstructive Pulmonary Disease, or Chronic Kidney Disease
Lead sponsor
National Cheng-Kung University Hospital
Phase
Observational
Overall status
Completed
Start date
May 6, 2020
Completion date
December 31, 2023
Enrollment
1,053 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

comorbidities and coexisting conditions, helicobacter pylori infection, medication adherence, patient compliance, patient dropouts, real-world outcome